WO2007014051A3 - Use of amylin and amylin agonists as cardioprotective or myoprotective agents - Google Patents
Use of amylin and amylin agonists as cardioprotective or myoprotective agents Download PDFInfo
- Publication number
- WO2007014051A3 WO2007014051A3 PCT/US2006/028410 US2006028410W WO2007014051A3 WO 2007014051 A3 WO2007014051 A3 WO 2007014051A3 US 2006028410 W US2006028410 W US 2006028410W WO 2007014051 A3 WO2007014051 A3 WO 2007014051A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amylin
- cardioprotective
- myoprotective
- agents
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Methods for provided for the use of amylin and amylin agonists as a cardioprotective agent. Compounds of the invention are used to reduce, prevent, or delay the mortality and/or morbidity associated with heart disease. Compounds of the invention are useful for treating or preventing cardiac and/or cardiovascular diseases. Compounds of the invention are useful for increasing or promoting the health of the heart.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06788137A EP1912666A2 (en) | 2005-07-22 | 2006-07-21 | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70148005P | 2005-07-22 | 2005-07-22 | |
US60/701,480 | 2005-07-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007014051A2 WO2007014051A2 (en) | 2007-02-01 |
WO2007014051A3 true WO2007014051A3 (en) | 2008-01-17 |
Family
ID=37311966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/028410 WO2007014051A2 (en) | 2005-07-22 | 2006-07-21 | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1912666A2 (en) |
WO (1) | WO2007014051A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010539051A (en) * | 2007-09-11 | 2010-12-16 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | Therapeutic use of intermedin 47 peptide and intermedin 53 peptide |
RU2010113968A (en) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | APPLICATION OF A PEPTIDE AS A THERAPEUTIC |
US20130143804A1 (en) * | 2010-06-07 | 2013-06-06 | Trustees Of The University Of Pennsylvania | Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus |
FR2961105B1 (en) * | 2010-06-15 | 2013-02-08 | Servier Lab | USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY |
AR101742A1 (en) | 2014-09-04 | 2017-01-11 | Novo Nordisk As | CALCITONINE AND AMILINE RECEIVER AGONIST |
JP6633777B2 (en) | 2017-08-24 | 2020-01-22 | ノヴォ ノルディスク アー/エス | GLP-1 compositions and uses thereof |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264372A (en) * | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
CN1282536A (en) * | 2000-08-29 | 2001-02-07 | 刘国柱 | Formula of nutritive carrot-gingko beverage and its preparing process |
CN1338216A (en) * | 2000-08-17 | 2002-03-06 | 郭立文 | Nutritive food for recovery |
WO2003057244A2 (en) * | 2002-01-08 | 2003-07-17 | Amylin Pharmaceuticals, Inc. | Use of amylin agonists to modulate triglycerides |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
WO2006105345A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
-
2006
- 2006-07-21 EP EP06788137A patent/EP1912666A2/en not_active Withdrawn
- 2006-07-21 WO PCT/US2006/028410 patent/WO2007014051A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264372A (en) * | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
CN1338216A (en) * | 2000-08-17 | 2002-03-06 | 郭立文 | Nutritive food for recovery |
CN1282536A (en) * | 2000-08-29 | 2001-02-07 | 刘国柱 | Formula of nutritive carrot-gingko beverage and its preparing process |
WO2003057244A2 (en) * | 2002-01-08 | 2003-07-17 | Amylin Pharmaceuticals, Inc. | Use of amylin agonists to modulate triglycerides |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
WO2006105345A2 (en) * | 2005-03-31 | 2006-10-05 | Amylin Pharmaceuticals, Inc. | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
Non-Patent Citations (5)
Title |
---|
CUPARENCU B ET AL: "Effect of calcitonin on experimental arrhythmias", THERAPIE 1975, vol. 30, no. 4, 1975, pages 555 - 563, XP009091896, ISSN: 0040-5957 * |
DATABASE WPI Week 200132, Derwent World Patents Index; AN 2001-300860, XP002457780 * |
DATABASE WPI Week 200243, Derwent World Patents Index; AN 2002-395405, XP002457779 * |
JIAN-FENG Z ET AL: "STABILIZATION OF CARDIAC RHYTHM IN SUBSEQUENTLY FATAL VENTRICULAR TACHYCARDIA AND FIBRILLATION BY CALCITONIN GENE-RELATED PEPTIDE", INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 34, no. 1, 1992, pages 101 - 103, XP002457777, ISSN: 0167-5273 * |
YOUNG ANDREW: "Cardiovascular effects.", ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2005, vol. 52, 2005, pages 239 - 250, XP009091642, ISSN: 1054-3589 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007014051A2 (en) | 2007-02-01 |
EP1912666A2 (en) | 2008-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006015159A3 (en) | Potassium channel inhibitors | |
WO2007014051A3 (en) | Use of amylin and amylin agonists as cardioprotective or myoprotective agents | |
WO2007018314A3 (en) | Therapeutic agent for diabetes | |
TW200708511A (en) | Novel thiophene derivatives | |
WO2007064931A3 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2007050348A3 (en) | Potassium channel inhibitors | |
WO2006073890A3 (en) | Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis | |
PL381247A1 (en) | Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application | |
WO2003094856A3 (en) | 1l1rl-1 as a cardiovascular disease marker and therapeutic target | |
ITRM20050265A1 (en) | MODULAR PROSTHESIS REFINED FOR OSTEOSYNTHESIS, IN PARTICULAR FOR THE OSTEOSYNTHESIS OF THE HUMERUS. | |
WO2006089871A3 (en) | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias | |
MX2007010560A (en) | Roflumilast for the treatment of diabetes mellitus. | |
WO2004075823A8 (en) | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | |
WO2006122046A3 (en) | Vascular disease therapies | |
IL190730A0 (en) | Potassium channel inhibitors | |
CL2008000594A1 (en) | USE OF COMPOUNDS DERIVED FROM HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, CORONARY ARTERIAL DISEASE BETWEEN OTHER DISEASES. | |
WO2005030129A3 (en) | Quinoline potassium channel inhibitors | |
BRPI0622419A2 (en) | pesticidal and / or herbicidal compositions and methods of using them. | |
CL2010001123A1 (en) | Use of pyridin-3-ylmethyl docosahexanoate to prepare a useful medicine for the prevention and / or treatment of cardiovascular diseases (divisional application 1848-07). | |
WO2007051785A3 (en) | Use of sdf-1 for the treatment and/or prevention of neurological diseases | |
WO2009074969A3 (en) | Spingosine-1-phosphate, analogues and antagonists for use as medicaments | |
WO2006019978A3 (en) | Compositions and methods for diagnosis and treatment of epilepsy | |
WO2006014877A3 (en) | Potassium channel inhibitors | |
WO2005030792A3 (en) | Quinoline potassium channel inhibitors | |
WO2006002846A3 (en) | New analogs of nitrobenzylthioinosine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006788137 Country of ref document: EP |